Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | BUB1 | O43683 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6203338 | 0.92 | CTSK (0.50) | CTSKPREPUSP2SMN1; SMN2CHRM2 | |
| SCHEMBL6023110 | 0.88 | CTSK (0.43) | CTSKPREPUSP2SMN1; SMN2CHRM2 | |
| SCHEMBL6023105 | 0.81 | CTSK (0.50) | CTSKPREPUSP2SMN1; SMN2CHRM2 | |
| SCHEMBL13523486 | 0.78 | CTSK (0.59) | CTSKPREPUSP2SMN1; SMN2CHRM2 | |
| SCHEMBL3603591 | 0.78 | CTSK (0.64) | CTSKPREPUSP2SMN1; SMN2CHRM2 | |
| SCHEMBL31703586 | 0.76 | TFPI2 (0.30) | — | |
| SCHEMBL29489783 | 0.76 | CTSK (0.40) | CTSKPREPUSP2SMN1; SMN2CHRM2 | |
| SCHEMBL222920 | 0.75 | PREP (0.53) | CTSKPREPUSP2SMN1; SMN2HPGD | |
| SCHEMBL900812 | 0.73 | CTSK (0.67) | CTSKPREPUSP2SMN1; SMN2CHRM2 | |
| SCHEMBL3603586 | 0.73 | CTSK (0.72) | CTSKPREPUSP2SMN1; SMN2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1257905-C | Compounds for inhibiting the release of inflammatory cytokines | PROCTER & GAMBLE (US) | 2006-05-31 | — | — | CN | disclosed |
| EP-1427727-B1 | COMPOUNDS WHICH INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES | PROCTER & GAMBLE (US) | 2005-01-26 | — | — | EP | disclosed |
| CN-1555375-A | compounds that inhibit inflammatory cytokine release | — | 2004-12-15 | — | — | CN | disclosed |
| US-6821971-B2 | FOR PROPHYALXIS OF RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, INFLAMMATORY BOWEL DISEASE (IBS), SEPTIC SHOCK, CARDIOPULMONARY DYSFUNCTION, ACUTE RESPIRATORY DISEASE, CACHEXIA | THE PROCTER & GAMBLE COMPANY | 2004-11-23 | — | — | US | disclosed |
| EP-1427727-A1 | COMPOUNDS WHICH INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES | THE PROCTER & GAMBLE COMPANY (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20030105084-A1 | Compound which inhibit the release of inflammatory cytokines | THE PROCTER & GAMBLE COMPANY | 2003-06-05 | — | — | US | disclosed |
| WO-2003024970-A1 | COMPOUNDS WHICH INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES | THE PROCTER & GAMBLE COMPANY (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105084-A1 | Compound which inhibit the release of inflammatory cytokines | IL1B, IL1A, TNF | CTSK 447/4885PREP 290/4885USP2 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.